O-glycoside Patents (Class 514/25)
  • Publication number: 20120082717
    Abstract: Disclosed herein is a complex, wherein micelles and/or liposomes dispersed in hyaluronic acids and/or hyaluronic acid derivatives, with a drug and/or functional material loaded in the micelles and/or the liposomes. The complex can release the drug and/or functional material in a controlled manner. Also, a multilayer using the complex, and a device coated with the multilayer are disclosed herein.
    Type: Application
    Filed: June 4, 2010
    Publication date: April 5, 2012
    Applicants: SNU R&DB FOUNDATION, ILJIN MATERIALS CO., LTD.
    Inventors: Kook Heon Char, Sai Bom Park, Jin Hwa Seo, Sang Beom Kim, Chong Su Seo
  • Publication number: 20120083459
    Abstract: Uses of exogenous ganglioside to inhibit the propagation of prostate cancer cells are provided. Gangliosides regulate many cellular processes including cell death. The present disclosure assesses the role of ganglioside in prostate cell growth. Malignant prostate (PC-3) and control (RWPE-1) cells can be cultured with or without ganglioside treatment. Cells can be assayed for differences in cell growth. Supplementation with ganglioside (GD3) can decrease growth of PC-3 cells by 30% compared to controls (p<0.01). Ganglioside can have therapeutic benefit in prostate cancer as demonstrated by decreased growth of malignant PC-3 cells.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 5, 2012
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Michael Thomas CLANDININ, John MIKLAVCIC, Vera MAZURAK
  • Patent number: 8148335
    Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: April 3, 2012
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Gregory R. Moe, Charles Paul Plested
  • Publication number: 20120077762
    Abstract: Disclosed herein are compounds, extracts, and active fractions of the plant Geum japonicum alone or in combination with Centella Asiatica and methods for preventing or treating heart failure. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are the use of the compounds and extracts in preparing pharmaceutical formulations and medicaments.
    Type: Application
    Filed: June 11, 2010
    Publication date: March 29, 2012
    Inventors: Ming Li, Zhongyu Li
  • Publication number: 20120071426
    Abstract: The present invention provides methods and compositions for treating lung cancer by cyclohexenone compounds.
    Type: Application
    Filed: March 23, 2011
    Publication date: March 22, 2012
    Applicant: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, San-Bao Hwang, Wu-Che Wen
  • Publication number: 20120070396
    Abstract: The present invention includes as an active ingredient at least one biosurfactant, in particular mannosyl alditol lipid (such as MEL and MML) or triacylated mannosyl alditol lipid. This allows providing an activator and anti-aging agent that is excellent in activating and anti-aging effects on cells and that is safe enough to be used for a long time, and also providing cosmetics, quasi-drugs, drugs, and drinks and foods including the activator and the anti-aging agent as active ingredients. Further, the present invention provides MEL whose mannosyl erythritol skeleton in a molecular structure is 1-O-?-D-mannopyranosyl-meso-erythritol and a method for producing the MEL with use of a microorganism.
    Type: Application
    Filed: October 19, 2011
    Publication date: March 22, 2012
    Applicants: National Institute of Advanced Industrial Science and Technology, TOYO BOSEKI KABUSHIKI KAISHA
    Inventors: Michiko Suzuki, Masaru Kitagawa, Shuhei Yamamoto, Atsushi Sogabe, Dai Kitamoto, Tomotake Morita, Tokuma Fukuoka, Tomohiro Imura
  • Publication number: 20120070497
    Abstract: Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-?-boswellic acid, 11-keto-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 9,11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof, a pharmaceutically acceptable salt thereof, a combination thereof, or a preparation containing one or more of these compounds) for the human medical or veterinary prophylaxis and/or treatment of: a) damage to and/or inflammation of the islets of Langerhans and/or b) damage to the B-cells of the islets of Langerhans.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 22, 2012
    Applicant: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.
    Inventor: Hermann P.T. Ammon
  • Publication number: 20120065152
    Abstract: Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for improving the pharmacokinetics of guanfacine or minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration are provided herein.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: SHIRE LLC
    Inventors: Rhys Whomsley, Bernard T. Golding, Robert G. Tyson
  • Publication number: 20120064044
    Abstract: Methods are described for preventing or reducing edema related to ischemia-reperfusion by treating the organ or tissue being transplanted with an aminoalkyl glucosaminide phosphate.
    Type: Application
    Filed: April 9, 2010
    Publication date: March 15, 2012
    Inventor: Thomas Michael Egan
  • Publication number: 20120058895
    Abstract: Biosurfactants produced by microbes are used to control pests. The biosurfactants can be produced by cultivating a biosurfactant-producing microbe, producing a fermentation broth, and obtaining the biosurfactant from the fermentation broth. Alternately, the biosurfactants can be produced in situ in the environment of the pests by applying a carbon substrate to the pests' environment, which permits naturally-occurring biosurfactant-producing microbes to grow and to generate the biosurfactants. The biosurfactants have pesticidal qualities, and can be used to control a variety of pests, while being biodegradable and otherwise avoiding adverse environmental effects that have often been associated with conventional synthetic pesticides.
    Type: Application
    Filed: June 29, 2011
    Publication date: March 8, 2012
    Applicant: AGSCITECH
    Inventors: Salam M. Awada, Mohamed M. Awada, Rex S. Spendlove
  • Publication number: 20120058123
    Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Application
    Filed: October 12, 2011
    Publication date: March 8, 2012
    Applicant: PANMIRA PHARMACEUTICALS, LLC.
    Inventors: John Howard HUTCHINSON, Brian Andrew Stearns, Jill Melissa Scott, Yen Pham Truong, Jeffrey Roger Roppe, Nicholas Simon Stock, Jeannie M. Arruda, Thomas Jon Seiders, Bowei Wang, Deborah Volkots
  • Publication number: 20120058960
    Abstract: Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan BOONS, Jun Guo
  • Publication number: 20120058087
    Abstract: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.
    Type: Application
    Filed: December 18, 2009
    Publication date: March 8, 2012
    Applicant: Kobenhavns Universitet
    Inventors: Morten Rønn Petersen, Anders Miki Bojesen
  • Publication number: 20120058148
    Abstract: Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.
    Type: Application
    Filed: May 24, 2011
    Publication date: March 8, 2012
    Applicant: Corixa Corporation
    Inventors: David A. Johnson, David Persing
  • Patent number: 8129350
    Abstract: A method of delaying digestion by an animal or a human of carbohydrates in food, comprising administering an effective amount of one or more flavonoids to the animal or human in conjunction with the food, wherein the flavonoids are selected from luteolin, apigenin, tricin and their pharmaceutically acceptable analogues and derivatives.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: March 6, 2012
    Assignee: Queen Bioactives Pty Ltd
    Inventors: Timothy Ralston Lang, Michael Gerard O'Shea
  • Patent number: 8128948
    Abstract: A composition containing suspensolide and optionally at least one of ?-hydroxy acid of epianastrephin, ?-hydroxy acid of anastrephin, 2,6-dimethyl-6-vinyl-cyclohexeneacetic acid, ?-D-glucopyranosyl 2,6-dimethyl-6-vinyl-cyclohex-1-ene-1-acetoate, or mixtures thereof, and optionally a carrier or carrier material; the composition contains no ?-bisabolene and no ?-farnesene. A method for attracting Anastrepha species (e.g., A. suspensa) involving treating an object or area with an Anastrepha species attracting effective amount of the above composition.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: March 6, 2012
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Peter E.A. Teal, Spencer S. Walse
  • Publication number: 20120053134
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases, and more particularly, to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases containing, as active ingredients, any one or two or more compounds selected from a group consisting of the compound of chemical formula 1, the compound of chemical formula 2, and the acceptable salts thereof. The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia.
    Type: Application
    Filed: May 6, 2010
    Publication date: March 1, 2012
    Inventors: Jae-Hoon Jung, Hyung-Ryong Moon
  • Patent number: 8124115
    Abstract: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ?99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of ±15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: February 28, 2012
    Assignee: DEP IP Limited
    Inventors: Marcel Veeger, Markus Himming
  • Patent number: 8124575
    Abstract: The present invention relates to a series of polyglycoside derivatives that are (a) polymeric (that is cross linked with hydroxypropyl linkages) and (b) contain additional functional groups including alkoxy, sulfate, sulfonate, quaternary and phosphate groups, and (c) sugars to increase water solubility and provide outstanding foaming agents and detergents that are naturally derived and readily biodegradable.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: February 28, 2012
    Assignee: SurfaTech Corporation
    Inventor: Anthony J. O'Lenick, Jr.
  • Publication number: 20120046238
    Abstract: A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a pharmaceutical composition including a coumarin compound.
    Type: Application
    Filed: November 10, 2011
    Publication date: February 23, 2012
    Applicant: National Health Research Institutes
    Inventors: Hsing-Pang Hsieh, Tsu-An Hsu, Jiann-Yih Yeh, Jim-Tong Horng, Shin-Ru Shih, Sui-yuan Chang, Yu-Sheng Chao
  • Publication number: 20120046237
    Abstract: Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, or chalconoid compounds, with appropriate substitutions of their hydroxyl groups to render them water soluble or in combination with a pshospholipid or cyclodextrin to render them to have higher oral absorption, administered alone or together with an anti-superficial vasodilation dose of one or more of, olive kernel oil, a serotonin inhibitor, a prostaglandin inhibitor, willow bark extract.
    Type: Application
    Filed: May 20, 2011
    Publication date: February 23, 2012
    Inventor: Theoharis C. THEOHARIDES
  • Publication number: 20120040897
    Abstract: A compound of formula (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof; wherein ‘a’—is selected from the group consisting of substituted or unsubstituted heterocycloalkyl ring and substituted or unsubstituted carbohydrate moiety y is a member selected from —O—, —CO—, —S02-, aminoalkyl or formula (II) wherein, Rw is hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; x is a member selected from -0-, —S—, —SO—, —S02-, CONR10, NR10CO and —NRd—, or x and y together represent a chemical bond; Z is selected from —CH—, —N—. t is an integer selected from O to 4; with the provisos that when ‘a’ is substituted or unsubstituted heterocycloalkyl ring then ‘t’ is not O and when y=—CO—, x is not NRd.
    Type: Application
    Filed: January 9, 2009
    Publication date: February 16, 2012
    Applicant: Sun Pharma Advanced Research Company Ltd.
    Inventors: Nakul Pramod Akolkar, Jay Prakashchandra Adhyapak, Javraj Dilipbhai Aradhye, Anil Savajihai Kumbhani, Bhavesh Mohanbhai Panchal, Jignesh Kantilal Jivani, Biswajit Samanta, Ranjan Kumar Pal, Rajamannar Thennati
  • Publication number: 20120040916
    Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/?-catenin pathway by selecting a subject with a condition mediated by the Wnt/?-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly inhibiting the Wnt/?-catenin pathway in a subject is also disclosed.
    Type: Application
    Filed: December 21, 2009
    Publication date: February 16, 2012
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTON
    Inventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
  • Publication number: 20120035118
    Abstract: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
    Type: Application
    Filed: August 2, 2011
    Publication date: February 9, 2012
    Applicant: ALTHERX, INC.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Publication number: 20120035120
    Abstract: This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.
    Type: Application
    Filed: March 25, 2010
    Publication date: February 9, 2012
    Applicant: SENEB BIOSCIENCES, INC.
    Inventor: Shawn DeFrees
  • Publication number: 20120035119
    Abstract: This application discloses natural product extracts and compounds from an aerial root of a Ficus plant, such as Ficus benghalensis. The application also discloses the use of natural product extracts and compounds from Ficus plants for increasing hair growth and decreasing hair loss. Synthetic formulations comprising various compounds identified in the natural product extracts and methods of use thereof are further disclosed.
    Type: Application
    Filed: September 19, 2011
    Publication date: February 9, 2012
    Applicant: Alvia FZE
    Inventors: Antonio Armani, Sara Armani, Charitha Seneviratne, Reza Nazari, Fernando Armani
  • Publication number: 20120028915
    Abstract: This invention relates to galactosylceramide compounds.
    Type: Application
    Filed: August 2, 2011
    Publication date: February 2, 2012
    Applicants: The Scripps Reseach Institute, The University of Chicago, Brigham Young University
    Inventors: Paul B. Savage, Ablert Bendelac, Luc Teyton
  • Publication number: 20120028914
    Abstract: A pharmaceutical composition including proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of H. pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics. The comprehensive treatment of ulcer disease associated with a helicobaterial infection using a pharmaceutical composition of a PPI and a prebiotic makes it possible, in conditions of an elevated pH of the stomach contents, actively to stimulate the growth of lactobacilli in the upper sections of the gastrointestinal tract, including the duodenum, and substantially to increase the titre of lactobacilli, which are antagonists of H. pylori, which greatly improves the effectiveness of the ulcer treatment.
    Type: Application
    Filed: April 23, 2010
    Publication date: February 2, 2012
    Inventors: Aleksander Vladimirovich Dikovskiy, Oleg Valentinovich Dorozhko
  • Patent number: 8106022
    Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: January 31, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Martin Maier
  • Patent number: 8106007
    Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: January 31, 2012
    Assignee: N.V. Organon
    Inventors: Ebo Sijbren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
  • Publication number: 20120022009
    Abstract: Dry powder tannate compositions containing bioactive agents, tannic acid, dispersants, and viscosity modifying agents are disclosed. Specifically, the bioactive agents are antihistamines, decongestants, antitussives, and anticholinergics. The dry powder formulations can further include pharmaceutically acceptable excipients. The dry powder formulations exhibit increased stability for extended shelf life. Bioactive agent tannate salts remain suspended for at least two weeks following formation of the suspension in a pharmaceutically acceptable aqueous liquid.
    Type: Application
    Filed: July 20, 2011
    Publication date: January 26, 2012
    Inventor: Thomas Jeffrey Bryant
  • Publication number: 20120021046
    Abstract: Mutual prodrugs of glucosamine, and derivatives and analogs of glucosamine and an anti-inflammatory agent, compositions thereof, and methods for, e.g., treating disorders and conditions by administration of the compositions are provided. Topical compositions of glucosamine, and derivatives and analogs of glucosamine are also provided.
    Type: Application
    Filed: September 9, 2011
    Publication date: January 26, 2012
    Inventors: Anthony C. Capomacchia, Solomon T. Garner, JR., J. Warren Beach
  • Publication number: 20120022008
    Abstract: Compounds extracted from Rhodiola rosea have ability to inhibit gelatinases and collagenases activity. The compounds have the chemical structure as shown below.
    Type: Application
    Filed: June 23, 2011
    Publication date: January 26, 2012
    Applicants: CHINA MEDICAL UNIVERSITY, TAIPEI MEDICAL UNIVERSITY (TMU)
    Inventors: Ching-Kuo Lee, Chieh-Chih Hsu, George Hsiao, Shin-Hun Juang
  • Publication number: 20120015011
    Abstract: Disclosed is a cosmetic composition having a double-shell type nano-structure. More particularly, the nano-structure of the cosmetic composition includes: a water-soluble bioactive ingredient core; a core shell containing poly(ethyleneglycol)-poly(caprolactone)-poly(ethyleneglycol) (PE-PCL-PEG) triblock copolymer in order to include the bioactive ingredient core therein; and an outer shell containing phospholipids or derivatives thereof in order to enclose the core shell therein. Such a cosmetic composition improves stability of active components which are prone to oxidation, light degradation, heat degradation, etc., is formed in a nanoparticle size which in turn shows high transdermal absorption and is very useful to prepare a cosmetic composition stably encapsulating various bioactive ingredients with anti-wrinkle effects, whitening effects, and so forth.
    Type: Application
    Filed: February 9, 2011
    Publication date: January 19, 2012
    Applicant: WOONGJIN COWAY CO., LTD.
    Inventors: Sung-Bo SHIM, Byoung-Young JEON, Joo-Hyuck LIM, Jong-Keun CHOI, Yong-Joon JOO, Jin-Hun CHO
  • Patent number: 8097593
    Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: January 17, 2012
    Assignee: Oncothyreon Inc.
    Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
  • Publication number: 20120009131
    Abstract: Isoacteoside or a pharmaceutically acceptable salt thereof is used to prevent or treat amyloid beta peptide-associated diseases or conditions as an agent for inhibiting formation, accumulation or aggregation of amyloid beta peptides.
    Type: Application
    Filed: June 15, 2011
    Publication date: January 12, 2012
    Applicant: Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou)
    Inventors: Hang-Ching LIN, Jing Jing Justine TANG, Muh-Hwan SU, Young-Ming HUANG
  • Patent number: 8092780
    Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: January 10, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
  • Patent number: 8093227
    Abstract: A monosaccharide compound of formula I as shown in the specification. Processes for the preparation of the compound of formula I and methods of screening for antibacterial or antibiotic compounds involving the compound of formula I.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 10, 2012
    Assignee: Alchemia Pty Ltd
    Inventors: Michael Leo West, Wim Meutermans, George Adamson, Karl Schafer, Darren Schliebs
  • Publication number: 20120004189
    Abstract: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.
    Type: Application
    Filed: June 1, 2011
    Publication date: January 5, 2012
    Applicants: AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITED, CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Kenneth David Reginald SETCHELL, Sidney John Cole
  • Patent number: 8088743
    Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: William N. Washburn, Jean Whaley, Mario Maldonado, James F. List, Frederick T. Fiedorek
  • Publication number: 20110311476
    Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 22, 2011
    Inventor: Joe Ernest BROWN
  • Patent number: 8080527
    Abstract: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: December 20, 2011
    Assignee: The Regents of the University of California
    Inventor: Michael David
  • Patent number: 8080539
    Abstract: A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: December 20, 2011
    Assignee: Scott and White Healthcare
    Inventor: Jules B. Puschett
  • Publication number: 20110306567
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.
    Type: Application
    Filed: August 24, 2009
    Publication date: December 15, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Joseph Schofield, Dave Smith, Patrick Soubayrol
  • Publication number: 20110306569
    Abstract: The present disclosure relates to an isolated strain of Pseudomonas aeruginosa strain NY3 and compounds produced by this strain having biosurfactant activity, for instance rhamnolipids Rha-C8-C8:1, Rha-C16, Rha-C16:1, Rha-C17:1, Rha-C24:1, Rha-Rha-C6-C6:1, Rha-Rha-C9:1, Rha-Rha-C10:1-C10:1, Rha-Rha-C24, and Rha-Rha-C24:1, as well as compositions of, derived from, comprising, or consisting of one or more of such compounds isolated from P. aeruginosa. Also provided are methods of treating environmental materials contaminated with hydrocarbons, heavy metals, or pesticides with such compositions and methods of inhibiting microbial growth with such compositions.
    Type: Application
    Filed: June 10, 2011
    Publication date: December 15, 2011
    Inventors: Xihou Yin, Maiqian Nie, Qirong Shen
  • Publication number: 20110306568
    Abstract: The invention relates to a composition containing 20 to 80% w/w of glucosyl-glycerol and 0.5 to 20% w/w of one or several mono- and/or disaccharides. Surprisingly, it has been found that an especially aqueous solution containing a high concentration of glucosylglycerol offers exceptionally high long-term stability. The composition has bactericidal and fungicidal effects.
    Type: Application
    Filed: October 28, 2009
    Publication date: December 15, 2011
    Inventors: Thomas Schwarz, Julia Klein
  • Patent number: 8076466
    Abstract: The present invention relates to fluorescent enzymatic substrates of saccharidic nature having a self-cleavable spacer arm functionalized by a fluorophore F and by at least one inhibitor of the fluorescence of F, to the use thereof for preparation of a diagnostic reagent for functional imaging in vivo, and to the diagnostic reagent for functional imaging containing at least one such enzymatic substrate.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: December 13, 2011
    Assignee: Commissariat a l'Energie Atomique
    Inventors: François Durrat, Isabelle Texier-Nogues, Véronique Robert
  • Publication number: 20110301104
    Abstract: Methods are provided for designing a transition state inhibitor of orotate phosphoribosyltransferase (OPRT) and for inhibiting OPRT.
    Type: Application
    Filed: November 18, 2009
    Publication date: December 8, 2011
    Inventor: Vern L. Schramm
  • Publication number: 20110300247
    Abstract: The invention relates compositions and methods for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans. Specifically, the invention relates to the dietary use of flaxseed lignans.
    Type: Application
    Filed: April 11, 2011
    Publication date: December 8, 2011
    Inventor: Melpo CHRISTOFIDOU-SOLOMIDOU
  • Publication number: 20110301105
    Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.
    Type: Application
    Filed: March 30, 2011
    Publication date: December 8, 2011
    Applicant: The Hospital for Sick Children
    Inventors: Freda Miller, David Kaplan, Kristen Smith, Maryline Paris, Sibel Naska